Literature DB >> 8086769

Neutrophil dysfunction in end-stage renal failure: reduced response to priming by C5a.

G J Dobos1, A E Traynor-Kaplan, D Ward, P J Schollmeyer.   

Abstract

We studied the effect of C5a pretreatment on phosphatidyl-inositol-4,5-bisphosphate (PIP2) hydrolysis and on the increase in peak and resting cytosolic calcium levels induced by C5a (0.1 and 10 nM) and/or N-formyl hexapeptide (FLPEP; 10 nM) in neutrophils isolated from patients with end-stage renal failure (ESRF) and those from healthy controls. We also investigated superoxide anion production under the same conditions using the fluorescent para-hydroxyphenylacetic acid assay. The hydrolysis of PIP2 induced by C5a or FLPEP alone was similar in neutrophils from patients with ESRF and in control cells. Likewise, pretreatment of patients' neutrophils with C5a prior to FLPEP did not affect hydrolysis or the increase in cytosolic calcium concentration as shown previously for control neutrophils. Resting calcium levels in both ESRF and control neutrophils, however, were significantly increased after priming with low C5a concentrations. After priming with low C5a, prior to FLPEP, there was also a significant increase in superoxide production. This increase was significantly lower in cells from uremic patients than in those from healthy controls. Our data suggest that priming-induced superoxide production in neutrophils is reduced in patients with ESRF.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8086769     DOI: 10.1007/bf00252827

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  21 in total

1.  Physicochemical characterization of a polypeptide present in uremic serum that inhibits the biological activity of polymorphonuclear cells.

Authors:  W H Hörl; M Haag-Weber; A Georgopoulos; L H Block
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

2.  The role of formylpeptide receptors, C5a receptors, and cytosolic-free calcium in neutrophil priming.

Authors:  W Zimmerli; A M Reber; C A Dahinden
Journal:  J Infect Dis       Date:  1990-02       Impact factor: 5.226

3.  Purification of polyphosphoinositides by chromatography on immobilized neomycin.

Authors:  J Schacht
Journal:  J Lipid Res       Date:  1978-11       Impact factor: 5.922

4.  Demographic analysis: end-stage renal disease and its treatment in the United States.

Authors:  B T Burton; G H Hirschman
Journal:  Clin Nephrol       Date:  1979-02       Impact factor: 0.975

5.  Defective immune and phagocytic functions in uraemia and renal transplantation.

Authors:  J McIntosh; P Hansen; J Ziegler; R Penny
Journal:  Int Arch Allergy Appl Immunol       Date:  1976

6.  Role of complement activation in a model of adult respiratory distress syndrome.

Authors:  S Hosea; E Brown; C Hammer; M Frank
Journal:  J Clin Invest       Date:  1980-08       Impact factor: 14.808

Review 7.  Inositol trisphosphate, a novel second messenger in cellular signal transduction.

Authors:  M J Berridge; R F Irvine
Journal:  Nature       Date:  1984 Nov 22-28       Impact factor: 49.962

8.  Anaphylatoxin formation during hemodialysis: comparison of new and re-used dialyzers.

Authors:  D E Chenoweth; A K Cheung; D M Ward; L W Henderson
Journal:  Kidney Int       Date:  1983-12       Impact factor: 10.612

9.  C5a receptor modulation on neutrophils and monocytes from chronic hemodialysis and peritoneal dialysis patients.

Authors:  S L Lewis; D E Van Epps; D E Chenoweth
Journal:  Clin Nephrol       Date:  1986-07       Impact factor: 0.975

10.  Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis.

Authors:  P R Craddock; J Fehr; K L Brigham; R S Kronenberg; H S Jacob
Journal:  N Engl J Med       Date:  1977-04-07       Impact factor: 91.245

View more
  2 in total

1.  Restoring glucose uptake rescues neutrophil dysfunction and protects against systemic fungal infection in mouse models of kidney disease.

Authors:  Chetan V Jawale; Kritika Ramani; De-Dong Li; Bianca M Coleman; Rohan S Oberoi; Saran Kupul; Li Lin; Jigar V Desai; Greg M Delgoffe; Michail S Lionakis; Filitsa H Bender; Alexander J Prokopienko; Thomas D Nolin; Sarah L Gaffen; Partha S Biswas
Journal:  Sci Transl Med       Date:  2020-06-17       Impact factor: 17.956

2.  Plasma calprotectin in chronically dialyzed end-stage renal disease patients.

Authors:  Karin Malícková; Helena Brodská; Jana Lachmanová; Sylvie Dusilová Sulková; Ivana Janatková; Helena Marecková; Vladimír Tesar; Tomás Zima
Journal:  Inflamm Res       Date:  2009-10-25       Impact factor: 4.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.